Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.

@article{Gao2007InfliximabTI,
  title={Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.},
  author={Qiang Gao and Martin J. W. Meijer and Ulrike G Schl{\"u}ter and Ruud A van Hogezand and Johanna M van der Zon and Marlies E Van den Berg and Wim van Duijn and Cornelis B. H. W. Lamers and Hein W. Verspaget},
  journal={Inflammatory bowel diseases},
  year={2007},
  volume={13 6},
  pages={693-702}
}
BACKGROUND Matrix metalloproteinases (MMPs) are actively involved in the pathogenesis of Crohn's disease (CD). We assessed the effect of the anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody infliximab on the in vitro and in vivo expression of MMP-2 and MMP-9 in CD. METHODS Infliximab-treated fistulizing (n = 10) or active disease (n = 7) CD patients, from an in-house study, and fistulizing CD patients (n = 42) and active CD patients (n = 24) from 2 placebo controlled studies… CONTINUE READING